CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gordon James who wrote (404)	11/26/1999 7:53:00 PM
From: Vector1	Read Replies (1) of 666

Gordon, Great post. One other factor that should be considered is that Neupogen is not an inexpensive drug. Payors will prefer Bex if it is likely to have fewer side effects require expensive treatments. I also have doubts as to IDPHs ability to complete its filing in June. As we know from the Bex application this these are complicated drugs with complicated manufacuring. Does anyone know who IDPH's Y supplier is. It will also be interesting to see how the two drugs are marketed. In order to not canabalize Rit it is likely that IDPH will only market Zev for refactory patients. On the other hand, despite having a refactory label on approval you can bet that CLTR will go after first line patients based on published studies combining Fludarabine and Bex. I will be very interested in seeing more complete and up to date Fludara plus Bex data at ASH. I hope everyone had a great holiday. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next